Log In
BCIQ
Print this Print this
 

G103

  Manage Alerts
Collapse Summary General Information
Company Immune Design Corp.
DescriptionVaccine composed of undisclosed recombinant proteins plus a synthetic glucopyranosyl lipid A (GLA) adjuvant
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationHerpes simplex virus (HSV)
Indication DetailsTreat herpes simplex virus type 2 (HSV-2) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/16/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today